Elevation Oncology reports Q4 EPS (19c), consensus (24c)

As of December 31, 2023, Elevation Oncology had cash, cash equivalents and marketable securities totaling $83.1M, compared to $90.3M as of December 31, 2022. “We are entering 2024 with tremendous momentum across our pipeline of differentiated ADC therapies,” said Joseph Ferra, President and CEO of Elevation Oncology. “We continue to advance EO-3021 and remain on-track to share an update from our Phase 1 clinical trial mid-year, as well as details on our combination strategy in the months ahead. In addition, we recently expanded our Phase 1 clinical trial into Japan, a geography with a particularly high prevalence of gastric cancer. This will allow us to potentially address a significant unmet need for new gastric cancer therapies outside of the U.S., while also enabling us to characterize the safety and efficacy profile of our anti-Claudin 18.2 agent in a diverse patient population.”